BRAF and melanoma: Although significant progress has been made to develop target therapy for melanoma, the mutations on N-RAS and B-RAF occurred in tumor cells have been a significant challenge for successful treatment of melanoma patients (Brose et al., 2002; Omholt et al., 2003; Thumar et al., 2014).